Plain-English translation of NCT06537999 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether (DNTH103), a new medication, can safely and effectively treat multifocal motor neuropathy—a rare condition where nerves gradually stop working properly, causing muscle weakness in different parts of your body. The study will compare the medication at two different doses against a placebo (an inactive pill) to see if it works and how well patients tolerate it.
Multifocal motor neuropathy is difficult to treat, and while some patients respond well to immunoglobulin therapy, not everyone improves enough or can continue that treatment long-term. This trial is testing whether this medication could offer a new option for people with this condition.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication at one of two doses or a placebo, given as an injection every two weeks. Throughout the study, you'll have regular visits to monitor how you're responding, check for any side effects, and complete tests to measure nerve and muscle function. The study will track how well the treatment works and gather information about its safety over time.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States